Insilico Medicine

Announcing the latest report from BioPharmaTrend: Insilico Medicine Celebrates Its 10th #AI-Driven Drug Candidate to Get FDA IND Clearance Insilico Medicine has announced FDA IND clearance for ISM5939, marking the 10th AI-designed drug candidate from the company to enter #clinicaltrials. The molecule, a novel oral #smallmolecule inhibitor targeting ENPP1, is designed for the treatment of solid #tumors. For the full report, please visit: https://bit.ly/3ZC25XW

💡 “Since Insilico’s foundation in 2014, I have seen, with my own eyes, lots of proof-of-concept cases in AI-driven drug discovery, and they are scattered across diseases areas and stages of the drug R&D process,” says Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. “The application of AI is revolutionizing the whole scientific research spectrum by enabling us to tackle complex challenges more efficiently and effectively, so that we’ll be living healthier, better, and more sustainable lives.” ➕ In 2016, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, which laid the foundation for the commercially available Pharma.AI platform. Since then, Insilico keeps integrating technical breakthroughs into Pharma.AI platform, which is currently a generative AI-powered solution spanning across #biology, #chemistry, medicine development and #scienceresearch. ⚡ Powered by Pharma.AI, Insilico has nominated 21 preclinical candidates in its comprehensive portfolio of over 30 assets since 2021 and has received #IND clearance for 10 molecules.  🔥 In early 2024, Insilico published a Springer Nature Biotechnology paper presenting the entire R&D journey from AI algorithms to #PhaseII clinical trials of ISM001-055, the company's lead drug pipeline with AI-discovered target and AI-designed structure. Following that, Insilico has recently announced positive preliminary results from a Phase IIa trial (NCT05938920), where ISM001-055 showed favorable safety and tolerability across all dose levels, as well as dose-dependent response in forced vital capacity (FVC), after only 12 weeks of dosage.  

 🚀 Happy New Year from the Science42: #DORA Team! We are happy to announce DORA 1.7.0 - Introducing the New #DORA Redesign We’re starting the new year with exciting updates and improvements! Thank you for choosing our platform. In 2025, we’re committed to enhancing your experience with even more powerful tools and features. Wishing you a successful and prosperous year ahead  📰 What’s New? -New Document Homepage Access the new Documents home page and #CustomBibliography tabs to easily upload, view, and manage your references independently from the document generation process. -New navigation: switch between template selection, other pages, and the main document page. -Optimized User info: Key account details are now conveniently accessible under your profile icon.   2. Revamped design for the #DocumentGeneration page, enhanced by the agent and resource selection feature. -Manage all document settings from a single, unified page -Redesigned input fields with detailed descriptions and helpful icons linking to an updated user manual. -Agents and resource selection: Select agents and their resources for data gathering, now available for every template. -Improved Custom #Dataintegration: A smoother process for adding custom data to specific template sections, with clear highlights of dependencies between predefined sections. -Smarter Research Task planning: Research plans now integrate seamlessly with your custom data. Enjoy an enhanced experience for manually adding, updating, and adjusting future document outlines. 3.  Updated Document count logic for paid users Document count now updates only when document generation begins. The current document availability is clearly displayed for paid users on the document page settings. Get Started with the New DORA Today! pharma.ai/dora

🔥 NEW Speaker Announcement! #PMWC2025 is just over a month away. Insilico CBO, Michelle Chen will join panelists from Verantos, Verily, and Khosla Ventures, part of the "Harnessing #AI in Real-World Data: Faster Trials and Post-Market Insights for #PrecisionMedicine" on February 6. This conference gathers recognized leaders, top global researchers and medical professionals, plus innovators across #healthcare and #biotechnology sectors. See the full agenda here, and be sure to register today! https://pmwcintl.com/ #SiliconValley #HealthcareEvents #TechEvents #AIEvents

💡 The Latest From Genetic Engineering & Biotechnology News 💡 Chemistry42 is an automated, machine-learning de novo drug design and scalable engineering platform, which according to the company, enables users to find novel lead-like molecules in as little as a week. Drawing on large numbers of compounds and molecular fragments, Chemistry42 uses #generativeAI to create new drug-like molecules optimized to have specific properties. Using the platform’s #Alchemistry module (https://lnkd.in/e8nZfyst), Insilico Medicine’s researchers initiated fragment growth by pre-establishing a priority fragment, the benzonitrile group, and six key pharmacological points based on the reported #PHD complex structures. By enhancing their novelty and synthetic availability filters, the researchers generated and screened hit compounds with activity deemed to be promising, then used Structure-Activity Relationship (SAR) analysis to optimize the properties of potential candidates. AIchemistry helped researchers assess the potency of those generated compounds to compute binding free-energy estimates for PHD2-ligand complexes. Next, investigators used the #ADMET module to collect key predicted properties, prioritizing low solubility and high clearance to minimize systemic exposure while retaining its moderate permeability for cell penetration. “The generative chemistry module identified a novel PHD inhibitor candidate scaffold, the Alchemistry module optimized its potency by refining the Insilico Medicine Restricted (Level 3) molecular structure, and the ADMET profiling module modeled the physiochemical and biological properties that led us to select an effective and safe gut-restrictive molecule,” Alex Zhavoronkov and colleagues reported in their paper. For the full release, please continue reading here: https://lnkd.in/eC76sYum #Chemistry42 #biologics #molecules #novelmolecules

📚 Unlock Your Research Potential with Science42: DORA Are you an academic student looking to accelerate your research? Meet DORA—the AI-powered tool designed to simplify and enhance your discovery process. 🔍 Why Choose DORA? Gain insights across biology, chemistry, and pharmacology Access AI-driven tools for hypothesis generation and validation Collaborate effortlessly with peers 🎉 Special Offer: Academic discounts available—because innovation should be accessible to all. 👉 Learn more and start today. Your next breakthrough is just a click away! 🚀 https://pharma.ai/dora #AIInAcademia #ResearchTools #LifeSciences #DORA #Science42

📢 Exciting news! The Insilico Medicine leadership team is heading to San Francisco for the 43rd Annual J.P. Morgan #Healthcare Conference! Our team of experts, including our Founder and CEO, Alex Zhavoronkov, PhD, and key leaders across business development, AI platforms, clinical development, and strategy, are ready to connect and share how we're transforming drug discovery and healthcare with AI. 🚀 💼 Interested in a meeting? Contact us at bd@insilico.com to book a session with the team. For Pharma.AI inquiries, please email: pharma.ai@insilicomedicine.com Let’s explore opportunities to collaborate and innovate together! We hope to see you in a few weeks. #JPM2025 #InsilicoMedicine #HealthcareInnovation #AIinHealthcare #Networking #SanFrancisco

🌍 As we step into 2025, Insilico Medicine reaffirms its commitment to sustainability and creating a healthier planet for all. Our mission is to develop and promote open source cutting-edge generative AI technologies for environmental sustainability. Together, let’s build a future where technology, health, and sustainability thrive hand in hand. 🌱✨ #InsilicoMedicine #Sustainability #AIforGood #Innovation #2025

Quote of the week 💬 Did you know that over 50% of drug discovery companies 🧬 are now integrating AI into their processes? In biotech, generative AI is revolutionizing molecule design, enabling researchers to create entirely new compounds with properties tailored to treat specific diseases—compounds that don’t exist in nature. This has the potential to cut drug development timelines by 40% ⏱️ and significantly reduce costs 💰. But the impact doesn’t stop at healthcare. AI is reshaping industries like manufacturing ⚙️, where predictive algorithms are improving efficiency by up to 30%, and renewable energy 🌱, optimizing systems to increase output by 20%. The possibilities are endless as AI transforms the way we innovate and solve global challenges. Which industry do you think will see the biggest AI-driven revolution next? 🤔 Source: https://bit.ly/3C2mQD7 #ArtificialIntelligence #AIStatistics #GenerativeAI #BiotechInnovation #FutureOfWork #TechForGood #AIForChange Alex Zhavoronkov Insilico Medicine

🌟 As 2025 approaches, we at Insilico Medicine are reflecting on a decade of groundbreaking #innovation! 🚀 Over the past 10 years, we’ve been at the forefront of using #AI to accelerate #drugdiscovery, tackle complex diseases, and redefine what’s possible in healthcare. Our journey has been fueled by passion, collaboration, and a shared vision to transform lives. ✨ Check out our 10-year innovation video to see the milestones, breakthroughs, and future vision that continue to drive us. Here’s to the next decade of innovation and impact! 🎉 #InsilicoMedicine #Innovation #AIinHealthcare #DrugDiscovery #2025 https://lnkd.in/eRQeu-Nv